Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Nature Communications

Volumn 6, Issue , 2015, Pages

  Tapper, William ^a,b   Jones, Amy V ^a,b   Kralovics, Robert ^c   Harutyunyan, Ashot S ^c   Zoi, Katerina ^d   Leung, William ^a,b   Godfrey, Anna L ^e,f   Guglielmelli, Paola ^g   Callaway, Alison ^b   Ward, Daniel ^b   Aranaz, Paula ^b   White, Helen E ^a,b   Waghorn, Katherine ^a,b   Lin, Feng ^a,b   Chase, Andrew ^a,b   Joanna Baxter, E ^e,f   MacLean, Cathy ^e,f   Nangalia, Jyoti ^e,f   Chen, Edwin ^e,f   Evans, Paul ^h   Short, Michael ^h   Jack, Andrew ^h   Wallis, Louise ⁱ   Oscier, David ⁱ   Duncombe, Andrew S ^j   Schuh, Anna ^k   Mead, Adam J ^l   Griffiths, Michael ^m,n   Ewing, Joanne ^o   Gale, Rosemary E ^p   Schnittger, Susanne ^q   Haferlach, Torsten ^q   Stegelmann, Frank ^r   Döhner, Konstanze ^r   Grallert, Harald ^s,t   Strauch, Konstantin ^s,u   Tanaka, Toshiko ^v   Bandinelli, Stefania ^w   Giannopoulos, Andreas ^d   Pieri, Lisa ^g   Mannarelli, Carmela ^g   Gisslinger, Heinz ^x   Barosi, Giovanni ^y   Cazzola, Mario ^y,z   Reiter, Andreas ^aa   Harrison, Claire ^ab   Campbell, Peter ^ac   Green, Anthony R ^e,f   Vannucchi, Alessandro ^g   Cross, Nicholas C P ^a,b   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF FLORENCE   (Italy)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^k NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁿ BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^o BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^p UNIVERSITY COLLEGE LONDON   (United Kingdom)

^q MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^r UNIVERSITY HOSPITAL ULM   (Germany)

^s INSTITUTE OF EPIDEMIOLOGY   (Germany)

^t GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^u UNIVERSITY OF MUNICH   (Germany)

^v NATIONAL INSTITUTE ON AGING   (United States)

^w SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^x MEDICAL UNIVERSITY OF VIENNA   (Austria)

^y FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^z UNIVERSITY OF PAVIA   (Italy)

^aa UNIVERSITY OF HEIDELBERG   (Germany)

^ab GUY S HOSPITAL   (United Kingdom)

^ac WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MECOM PROTEIN; PROTEIN; PROTEIN MYB; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CALRETICULIN; CALRETICULIN, HUMAN; DNA BINDING PROTEIN; ELONGATION FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HBS1 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 70; JAK2 PROTEIN, HUMAN; MECOM PROTEIN, HUMAN; MPL PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR;

GENE EXPRESSION; GENETIC VARIATION; GENOME; MUTATION; PLASMA;

ADULT; ARTICLE; ATTRIBUTABLE RISK; BONE MARROW CELL; CANCER SUSCEPTIBILITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE NEOPLASM; PHENOTYPE; POLYCYTHEMIA VERA; QUALITY CONTROL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTHEMIA; AGED; ALLELE; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; ONCOGENE MYB; PROTO ONCOGENE;

ADULT; AGED; ALLELES; CALRETICULIN; CASE-CONTROL STUDIES; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENES, MYB; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GTP-BINDING PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PEPTIDE ELONGATION FACTORS; POLYCYTHEMIA VERA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENES; RECEPTORS, THROMBOPOIETIN; TELOMERASE; THROMBOCYTHEMIA, ESSENTIAL; TRANSCRIPTION FACTORS;

EID: 84927153553     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7691     Document Type: Article

References (69)

1. Vardiman, J. W., Harris, N. L. & Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100, 2292-2302 (2002).
2. Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl. J. Med. 369, 2379-2390 (2013).
3. Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl. J. Med. 369, 2391-2405 (2013).
4. Landgren, O. et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 112, 2199-2204 (2008).
5. Bellanné-Chantelot, C. et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108, 346-352 (2006).
6. Rumi, E. et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J. Clin. Oncol. 25, 5630-5635 (2007).
7. Jones, A. V. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 41, 446-449 (2009).
8. Olcaydu, D. et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 41, 450-454 (2009).
9. Olcaydu, D. et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23, 1924-1926 (2009).
10. Jones, A. V. et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115, 4517-4523 (2010).
11. Oddsson, A. et al. The germline sequence variant rs2736100-C in TERT associates with myeloproliferative neoplasms. Leukemia 28, 1371-1374 (2014).
12. Purcell, S., Cherny, S. S. & Sham, P. C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19, 149-150 (2003).
13. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289-300 (1995).
14. Gieger, C. et al. New gene functions in megakaryopoiesis and platelet formation. Nature 480, 201-208 (2011).
15. Qayyum, R. et al. A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. PLoS Genet. 8, e1002491 (2012).
16. García, P. et al. Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J. 28, 1492-1504 (2009).
17. Chen, E. et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential JAK2 signalling. Cancer Cell 18, 524-535 (2010).
18. Degner, J. F. et al. DNaseI sensitivity QTLs are a major determinant of human expression variation. Nature 482, 390-394 (2012).
19. Harrison, C. N. et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New Engl. J. Med. 353, 33-45 (2005).
20. Stegelmann, F. et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25, 1217-1219 (2011).
21. Varricchio, L. et al. Increased frequency of the glucocorticoid receptor A3669G (rs6198) polymorphism in patients with Diamond-Blackfan anemia. Blood 118, 473-474 (2011).
22. Poletto, V. et al. A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood 120, 3112-3117 (2012).
23. Gröschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157, 369-381 (2014).
24. Secker-Walker, L. M., Mehta, A. & Bain, B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J. Haematol. 91, 490-501 (1995).
25. Morishita, K., Parganas, E., Matsugi, T. & Ihle, J. N. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol. Cell Biol. 12, 183-189 (1992).
26. Shimizu, S. et al. EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem. Biophys. Res. Commun. 292, 609-616 (2002).
27. Albers, C. A. et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat. Genet. 44, 435-439 S1-2 (2012).
28. Emambokus, N. et al. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J. 22, 4478-4488 (2003).
29. Wallrapp, C. et al. The product of the mammalian orthologue of the Saccharomyces cerevisiae HBS1 gene is phylogenetically related to eukaryotic release factor 3 (eRF3) but does not carry eRF3-like activity. FEBS Lett. 440, 387-392 (1998).
30. Craig, J. E. et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. Nat. Genet. 12, 58-64 (1996).
31. Menzel, S. et al. The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans. Blood 110, 3624-3626 (2007).
32. Ganesh, S. K. et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat. Genet. 41, 1191-1198 (2009).
33. Soranzo, N. et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat. Genet. 41, 1182-1190 (2009).
34. Ferreira, M. A. et al. Sequence variants in three loci influence monocyte counts and erythrocyte volume. Am. J. Hum. Genet. 85, 745-749 (2009).
35. Frampton, M. et al. Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma. Nat. Commun. 4, 2549 (2013).
36. Wahlberg, K. et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 114, 1254-1262 (2009).
37. Farrell, J. J. et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood 117, 4935-4945 (2011).
38. Stadhouders, R. et al. Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development. EMBO J. 31, 986-999 (2012).
39. Thein, S. L. et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc. Natl Acad. Sci. USA 104, 11346-1151 (2007).
40. Lu, J. et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev. Cell 14, 843-853 (2008).
41. Godfrey, A. L. et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 120, 2704-2707 (2012).
42. Zaleskas, V. M. et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PLoS ONE 1, e18 (2006).
43. Klampfl, T. et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118, 167-176 (2011).
44. Holle, R., Happich, M., Löwel, H. & Wichmann, H. E. MONICA/KORA Study Group. KORA--a research platform for population based health research. Gesundheitswesen 67, S19-S25 (2005).
45. Ferrucci, L. et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J. Am. Geriatr. Soc. 48, 1618-1625 (2000).
46. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
47. Becker, R. A., Chambers, J. M. & Wilks, A. R. The New S Language: A Programming Environment for Data Analysis and Graphics (Wadsworth & Brooks/Cole, 1988).
48. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
49. Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336-2337 (2010).
50. Ma, X., Vanasse, G., Cartmel, B., Wang, Y. & Selinger, H. A. Prevalence of polycythemia vera and essential thrombocythemia. Am. J. Hematol. 83, 359-362 (2008).
51. Harris, R. et al. Metan: fixed-and random-effects meta-analysis. Stat. J. 8, 3-28 (2008).
52. Thompson, S. G. & Higgins, J. P. How should meta-regression analyses be undertaken and interpreted? Stat. Med. 21, 1559-1573 (2002).
53. Matakidou, A. et al. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis 25, 369-373 (2004).
54. Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 17, 1665-1674 (2007).
55. Staaf, J. et al. Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol. 9, R136 (2008).
56. Jones, A. V. et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107, 3339-3341 (2006).
57. Harrison, C. N. et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br. J. Haematol. 149, 352-375 (2010).
58. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
59. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
60. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
61. ENCODE Project Consortium et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
62. Bernstein, B. E. et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 28, 1045-1048 (2010).
63. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 22, 1790-1797 (2012).
64. Paul, D. S. et al. Maps of open chromatin guide the functional follow-up of genome-wide association signals: application to hematological traits. PLoS Genet. 7, e1002139 (2011).
65. Paul, D. S. et al. Maps of open chromatin highlight cell type-restricted patterns of regulatory sequence variation at hematological trait loci. Genome Res. 23, 1130-1141 (2013).
66. Watkins, N. A. et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood 113, e1-e9 (2009).
67. Bagger, F. O. et al. HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res. 41, D1034-D1039 (2013).
68. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011).
69. Yang, T. P. et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26, 2474-2476 (2010).